



## Immature Teratoma Pathology Conference

Sunday, November 15, 2020

9:00 AM – 3:00 PM

### Meeting Purpose

---

The purpose of this meeting will be to better define the pathology of immature teratomas. The conference will be centered on consensus building around the following topics:

#### **Grading of Immature Teratomas:**

- How reproducible is grading?
- What is the inter-observer and intra-observer variability?
- Does classifying a low grade versus high grade seem more reasonable?

#### **Somatic transformation of IT:**

- How do we define IT with somatic transformation?
- How do we clearly differentiate grade III IT from PNET?

#### **Microscopic Foci of Yolk Sac Tumor:**

- Should presence of microscopic foci of malignant elements still define tumor as IT, or should they be classified as mixed malignant GCT?
- If microscopic foci of YST are acceptable to still define as IT, how do we define these microscopic foci?

#### **Tumor markers and IT:**

- Does an elevated AFP correlate with YST foci?



## Tentative Agenda

<b>Time</b>	<b>Topic</b>	<b>Pathology Lead</b>	<b>Clinician Lead</b>
<b>09:00 – 09:30</b>	Introductions, MaGIC Overview & Objectives and Agenda for the Day	<i>Krisztina Hanley</i>	<i>Farzana Pashankar</i>
<b>09:30 – 09:45</b>	Recent WHO Updates Review of Grading Definitions	<i>Russell Vang</i>	
<b>09:45 - 10:15</b>	Pathology Case Examples		
<b>10:15 – 11:45</b>	IT Grading Reproducibility of grade  Pro 2-tiered / Con 3-tiered  Con 2-tiered / Pro 3-tiered	<i>Kim Hazard</i>  <i>Heather Rytting</i> <i>Russell Vang</i> <i>Esther Elishaev</i> <i>Krisztina Hanley</i>	<i>Farzana Pashankar</i> <i>Michelle Lockley</i>
<b>11:45 – 12:15</b>	Break		
<b>12:15 – 01:00</b>	PNET Distinction from IT / Terminology	<i>Michelle Hirsch</i>	<i>Jennifer Veneris</i>
<b>01:00 – 01:45</b>	Microscopic Foci of YST / other GCT elements	<i>Miguel Reyes-Múgica</i> <i>Marisa Nucci</i>	<i>Michelle Lockley</i>
<b>01:45 – 02:00</b>	Break		
<b>02:00 – 02:45</b>	Biomarkers in IT – Pathology and Serum	<i>Miguel Reyes-Múgica</i> <i>Marisa Nucci</i>	<i>Sara Stoneham</i>
<b>02:45 – 03:00</b>	Conclusions		

---

**Meeting Attendees**

---

**Alyaa Al-Ibraheemi**

*Pediatric Pathology, Boston Children's Hospital*

**Rupali Arora**

*Gynecologic Pathology, University College Hospitals London*

**Deb Billmire**

*Pediatric Surgery, Indiana University*

**Al Covens**

*Gynecologic Oncology, University of Toronto*

**Esther Elishaev**

*Gynecologic Pathology, University of Pittsburgh*

**Lindsay Frazier**

*Pediatric Oncology, Dana-Farber Cancer Institute*

**Kirsztina Hanley**

*Gynecologic Pathology, Emory University Hospitals*

**Kim Hazard**

*Pediatric Pathology, Stanford University Medical Center*

**Michelle Hirsch**

*Genito-urinary/Gynecologic Pathology, Brigham and Women's Hospital*

**Michelle Lockley**

*Gynecologic Oncology, University College Hospital*

**Marissa Nucci**

*Gynecologic Pathology, Brigham and Women's Hospital*

**Tom Olson**

*Pediatric Oncology, Children's Healthcare of Atlanta*

**Farzana Pashankar**

*Pediatric Oncology, Yale University*

**Miguel Reyes -Múgica**

*Pediatric Pathology, University of Pittsburgh*

**Heather Rytting**

*Pediatric Pathology Children's Healthcare of Atlanta*

**Sara Stoneham**

*TYA Oncology, University College Hospitals London*

**Russel Vang**

*Gynecologic Pathology, Johns Hopkin Medicine*

**Jennifer Veneris**

*Gynecologic Oncology, Dana-Farber Cancer Institute*